These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36609061)

  • 21. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
    Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.
    Dohopolski M; Hannan R; Wardak Z; Hammers H; Garant A
    Cancer J; 2020; 26(5):448-459. PubMed ID: 32947313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
    Miccio J; Johung K
    Oncology (Williston Park); 2019 May; 33(5):167-73, 177. PubMed ID: 31095714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation therapy options in kidney cancer.
    Zaorsky NG; Louie AV; Siva S
    Curr Opin Support Palliat Care; 2023 Dec; 17(4):308-314. PubMed ID: 37877449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
    Uhlig A; Uhlig J; Trojan L; Kim HS
    J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.
    Franzese C; Francolini G; Nicosia L; Alongi F; Livi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):50-56. PubMed ID: 32723486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.
    Maclean J; Breau RH; Scheida N; Malone S
    BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25199199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SBRT in Localized Renal Carcinoma: A Review of the Literature.
    DE LA Pinta C; Latorre RG; Fuentes R
    Anticancer Res; 2022 Feb; 42(2):667-674. PubMed ID: 35093865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA.
    Haque W; Verma V; Lewis GD; Lo SS; Butler EB; Teh BS
    Future Oncol; 2018 Apr; 14(9):819-827. PubMed ID: 29527938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma.
    Reddy AV; Mills MN; Liauw SL; Baliga S; Kersh CR
    Can J Urol; 2019 Apr; 26(2):9743-9745. PubMed ID: 31012841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy for renal-cell carcinoma.
    De Meerleer G; Khoo V; Escudier B; Joniau S; Bossi A; Ost P; Briganti A; Fonteyne V; Van Vulpen M; Lumen N; Spahn M; Mareel M
    Lancet Oncol; 2014 Apr; 15(4):e170-7. PubMed ID: 24694640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
    Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
    Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.
    Onal C; Guler OC; Hurmuz P; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
    Strahlenther Onkol; 2022 Oct; 198(10):940-948. PubMed ID: 35695908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
    Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.